Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for ROSGQ. Our analysts highlight strong fundamentals and favorable market sentiment, positioning ROSGQ for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: ROSGQ is a Strong Buy candidate.
ROSGQ stock price ended at $0 on 星期三, after rising NaN%
On the latest trading day Jan 07, 2026, the stock price of ROSGQ rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 4.6K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 5.0K shares were traded, equating to a market value of approximately --.